The information within this section of the website is intended for UK Healthcare Professionals. UK Practice Managers should follow the relevant links.

Picking Prostap DCS for breast cancer

Prostap DCS at a glance

Prostap DCS (leuprorelin acetate):

  • Has treated over 24 million patients globally since 1996, across all licensed indications1
  • Has a well-established tolerability profile2,3
  • Includes a device that is easy to use, and designed with patient and user experience in mind2,3
  • Helps protect HCPs from needle stick injuries. Prostap DCS is fitted with a safety device that complies with the latest EU sharps directive and UK legislation2-5

About Prostap DCS2,3

  • Dual Chamber Syringe (DCS) system delivering leuprorelin2,3

Therapeutic indications2,3

Breast cancer

  • Treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation
  • Adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement)

Note: In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.

Endometriosis

  • Management of endometriosis, including pain relief and reduction of endometriotic lesions
  • Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection (Prostap SR DCS only)
  • Preoperative management of uterine fibroids to reduce their size and associated bleeding (Prostap SR DCS only)

Preservation of ovarian function

  • Use in pre-menopausal women with neoplastic disease undergoing chemotherapy treatment that can cause premature ovarian insufficiency (Prostap SR DCS only)

NOTE: Treatment with a GnRH analogue should only be proposed after careful risk/benefit evaluation in each patient. Not a replacement for standard fertility-preservation methods.

Prostate cancer

  • Metastatic prostate cancer
  • Locally advanced prostate cancer, as an alternative to surgical castration
  • As an adjuvant treatment to radiotherapy in patients with high risk localised or locally advanced prostate cancer
  • As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
  • As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer

Central precocious puberty

  • Central precocious puberty in girls under 9 years of age and boys under 10 years of age

Administration overview2,3

Intramuscular (IM) or subcutaneous (SC) administration available, depending on indication and dose

 

Dosage form

Released from micro particles that are 20µm in diameter6 abriefproductoverview-figure13

Needle size

Fine gauge needleImage not to scale

Dosing – Prostap SR DCS2

Dosing – Prostap 3 DCS3

Contact

If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. Takeda UK Ltd. Data on file, DF120604(2).
  2. Prostap SR DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
  3. Prostap 3 DCS. Summary of Product Characteristics. Available at: www.medicines.org.uk
  4. Health and Safety Executive. Health and Safety (Sharp Instruments in Healthcare) Regulations 2013. Available via: www.hse.gov.uk/pubns/hsis7.pdf (last accessed May 2019).
  5. European Agency for Safety and Health at Work. Directive 2010/32/EU – prevention from sharp injuries in the hospital and healthcare sector. Available at: www.osha.europa.eu/en/legislation/directives/council-directive-2010-32-eu-prevention-from-sharp-injuries-in-the-hospital-and-healthcare-sector (last accessed May 2019).
  6. Ogawa Y et al. J Pharm 1989;41(7):439-44.
  7. Abouelfadel Z & Crawford D. Therapeut Clin Risk Manag 2008;4(2):513-26.
  8. The Leuprolide Study Group. N Eng J Med 1984;311:1281-6.
  9. Friedman AJ et al. Fertil Steril 1987;48(4):560-4.
  10. PharmaTimes online. Takeda launces new presentation of Prostap, 2011. Available at: http://www.pharmatimes.com/news/takeda_launches_new_presentation_of_prostap_980760 (last accessed May 2019).
  11. National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and management. NICE guideline (CG175).
  12. Goel S et al. Cochrane Database Syst Rev 2009;7(4):CD004562.
  13. Cancer Research UK. Hormone therapy for cancer, June 2017. Available at: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/hormone-therapy/for-cancer (last accessed May 2019).
  14. NHS UK. Breast cancer in women – Treatment, September 2016. Available at: https://www.nhs.uk/conditions/breast-cancer/treatment/ (last accessed May 2019).
  15. Zoladex 3.6 mg. AstraZeneca UK. Summary of Product Characteristics. Available at: www.medicines.org.uk
  16. Decapeptyl SR 3 mg. Ipsen Ltd. Summary of Product Characteristics. Available at: www.medicines.org.uk

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers. If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a Practice Manager

Yes

I am a Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a
Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

Yes

I am a Healthcare Professional interested in breast cancer

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.